Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Acutus Medical, Inc.AFIB · Entity 83848 | Director | June 15, 2023 | June 15, 2023 |
| TANDEM DIABETES CARE INCTNDM · Entity 4682 | Director · PRESIDENT & CEO | August 15, 2026 | August 18, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Acutus Medical, Inc.
Report date June 15, 2023 · Filed June 15, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| FORM 4SEC Table I · non-derivative | Direct | 24,347 |
Reported balance
After 2023-06-15 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2023-06-15 · Grant · Acquired 8,400 · Balance 24,347 F1: Common Stock F2: Each annual restricted stock unit ("Annual RSU") will be scheduled to vest as to all of the Shares of Common Stock ("Shares) subject to such Annual RSU on the first anniversary of the date of grant of such Annual RSU, if on such date the Reporting Person has remained in continuous service as a director. |
| FORM 4SEC Table II · derivative / convertible security · Conversion / exercise price $0.83 · Expires 2033-06-15 | Direct | 19,600 |
Reported balance
After 2023-06-15 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-06-15 · Grant · Acquired 19,600 · Balance 19,600 F3: Stock Options (Right to Buy) F4: Each annual stock option ("the Annual Option") will be scheduled to vest and become exercisable as to all of the Shares subject to such Annual Option on the first anniversary of the date of grant of such Annual Option, fi on such date the Reporting Person has remained in continuous service as director. F1: Common Stock |
Filing footnotes · ownership attribution and instrument terms
F1: Common Stock
F2: Each annual restricted stock unit ("Annual RSU") will be scheduled to vest as to all of the Shares of Common Stock ("Shares) subject to such Annual RSU on the first anniversary of the date of grant of such Annual RSU, if on such date the Reporting Person has remained in continuous service as a director.
F3: Stock Options (Right to Buy)
F4: Each annual stock option ("the Annual Option") will be scheduled to vest and become exercisable as to all of the Shares subject to such Annual Option on the first anniversary of the date of grant of such Annual Option, fi on such date the Reporting Person has remained in continuous service as director.
TANDEM DIABETES CARE INC
Report date August 15, 2026 · Filed August 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 160,260 |
Ending reported balance
After 2026-08-15 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2026-08-15 · Exercise / conversion · Acquired 5,982 · Balance 158,425 Row 2 · 2026-08-15 · Tax withholding · Disposed 3,044 · Balance 155,381 F1: Shares withheld by the Issuer to satisfy tax withholding requirements upon the vesting of restricted stock units (RSUs). No shares were sold. Row 3 · 2026-08-15 · Exercise / conversion · Acquired 9,934 · Balance 165,315 Row 4 · 2026-08-15 · Tax withholding · Disposed 5,055 · Balance 160,260 F1: Shares withheld by the Issuer to satisfy tax withholding requirements upon the vesting of restricted stock units (RSUs). No shares were sold. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 17,947 |
Reported balance
After 2026-08-15 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-08-15 · Exercise / conversion · Disposed 5,982 · Balance 17,947 F2: Awarded on May 23, 2024 pursuant to the Tandem Diabetes Care Inc. 2023 Long-Term Incentive Plan, as amended, and agreements related thereto (the 2023 Plan). F3: Each RSU represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2023 Plan. F4: One-third of the RSUs granted on May 23, 2024 vested on May 15, 2025, with the remaining RSUs vesting in eight (8) equal quarterly installments thereafter, subject to the terms of the 2023 Plan. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 69,537 |
Reported balance
After 2026-08-15 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-08-15 · Exercise / conversion · Disposed 9,934 · Balance 69,537 F5: Awarded on May 30, 2025 pursuant to the 2023 Plan. F3: Each RSU represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2023 Plan. F6: One-third of the RSUs granted on May 30, 2025 vested on May 15, 2026, with the remaining RSUs vesting in eight (8) equal quarterly installments thereafter, subject to the terms of the 2023 Plan. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares withheld by the Issuer to satisfy tax withholding requirements upon the vesting of restricted stock units (RSUs). No shares were sold.
F2: Awarded on May 23, 2024 pursuant to the Tandem Diabetes Care Inc. 2023 Long-Term Incentive Plan, as amended, and agreements related thereto (the 2023 Plan).
F3: Each RSU represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2023 Plan.
F4: One-third of the RSUs granted on May 23, 2024 vested on May 15, 2025, with the remaining RSUs vesting in eight (8) equal quarterly installments thereafter, subject to the terms of the 2023 Plan.
F5: Awarded on May 30, 2025 pursuant to the 2023 Plan.
F6: One-third of the RSUs granted on May 30, 2025 vested on May 15, 2026, with the remaining RSUs vesting in eight (8) equal quarterly installments thereafter, subject to the terms of the 2023 Plan.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 15, 2025 Filed May 19, 2025 22:06 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | GrantCommon Stock | 1,359 | $15.64 | $21,254.76 |
DisclosureSEC source: 0001438133-25-000085 · wk-form4_1747692353.xml · nonDerivative · entry 1 Sheridan John F · CIK 0001365369 · Director · PRESIDENT & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,368 F1 · acquired: The reporting person is voluntarily reporting the acquisition of shares of common stock pursuant to the Tandem Diabetes Care, Inc. Amended and Restated 2013 Employee Stock Purchase Plan (ESPP), for the ESPP purchase period of November 18, 2024, through May 15, 2025. This transaction is also exempt under Rule 16b-3(c). Read SEC document |
| February 25, 2025 Filed Feb 27, 2025 22:15 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | Exercise / conversionPerformance Stock Unit · Derivative | 26,047 | $0.00 | $0.00 |
DisclosureSEC source: 0001438133-25-000037 · wk-form4_1740694513.xml · derivative · entry 6 Sheridan John F · CIK 0001365369 · Director · PRESIDENT & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 26,047 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · security: Awarded on May 25, 2022 pursuant to the 2013 Plan. F3 · derivative.exercise_price: Each PSU represents a contingent right to receive one share of the Company common stock based upon the achievement of certain pre-defined performance metrics as of December 31, 2024 (the Measurement Date). The number of shares issued may range from 0% to 200% of the base grant amount, based upon (i) Company's actual performance relative to the pre-defined performance metrics, and (ii) subject to the awardee's continuing service through the Measurement Date. If minimum performance metrics are not met, no PSUs will vest. F3 · derivative.exercise_date: Each PSU represents a contingent right to receive one share of the Company common stock based upon the achievement of certain pre-defined performance metrics as of December 31, 2024 (the Measurement Date). The number of shares issued may range from 0% to 200% of the base grant amount, based upon (i) Company's actual performance relative to the pre-defined performance metrics, and (ii) subject to the awardee's continuing service through the Measurement Date. If minimum performance metrics are not met, no PSUs will vest. F3 · derivative.expiration_date: Each PSU represents a contingent right to receive one share of the Company common stock based upon the achievement of certain pre-defined performance metrics as of December 31, 2024 (the Measurement Date). The number of shares issued may range from 0% to 200% of the base grant amount, based upon (i) Company's actual performance relative to the pre-defined performance metrics, and (ii) subject to the awardee's continuing service through the Measurement Date. If minimum performance metrics are not met, no PSUs will vest. Read SEC document |
| February 25, 2025 Filed Feb 27, 2025 22:15 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | Exercise / conversionPerformance Stock Unit · Derivative | 6,732 | $0.00 | $0.00 |
DisclosureSEC source: 0001438133-25-000037 · wk-form4_1740694513.xml · derivative · entry 5 Sheridan John F · CIK 0001365369 · Director · PRESIDENT & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,732 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Awarded on May 18, 2021 pursuant to the Tandem Diabetes Care, Inc. 2013 Stock Incentive Plan, as amended, and the agreements related thereto (the 2013 Plan). F3 · derivative.exercise_price: Each PSU represents a contingent right to receive one share of the Company common stock based upon the achievement of certain pre-defined performance metrics as of December 31, 2024 (the Measurement Date). The number of shares issued may range from 0% to 200% of the base grant amount, based upon (i) Company's actual performance relative to the pre-defined performance metrics, and (ii) subject to the awardee's continuing service through the Measurement Date. If minimum performance metrics are not met, no PSUs will vest. F3 · derivative.exercise_date: Each PSU represents a contingent right to receive one share of the Company common stock based upon the achievement of certain pre-defined performance metrics as of December 31, 2024 (the Measurement Date). The number of shares issued may range from 0% to 200% of the base grant amount, based upon (i) Company's actual performance relative to the pre-defined performance metrics, and (ii) subject to the awardee's continuing service through the Measurement Date. If minimum performance metrics are not met, no PSUs will vest. F3 · derivative.expiration_date: Each PSU represents a contingent right to receive one share of the Company common stock based upon the achievement of certain pre-defined performance metrics as of December 31, 2024 (the Measurement Date). The number of shares issued may range from 0% to 200% of the base grant amount, based upon (i) Company's actual performance relative to the pre-defined performance metrics, and (ii) subject to the awardee's continuing service through the Measurement Date. If minimum performance metrics are not met, no PSUs will vest. Read SEC document |
| February 25, 2025 Filed Feb 27, 2025 22:15 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | Tax withholdingCommon Stock | 10,008 | $33.34 | $333,666.72 |
DisclosureSEC source: 0001438133-25-000037 · wk-form4_1740694513.xml · nonDerivative · entry 4 Sheridan John F · CIK 0001365369 · Director · PRESIDENT & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 79,009 F1 · kind: Shares withheld by Tandem Diabetes Care, Inc. (the Company) to satisfy tax withholding requirements on vesting of performance stock units (PSU). No shares were sold. Read SEC document |
| February 25, 2025 Filed Feb 27, 2025 22:15 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | Exercise / conversionCommon Stock | 26,047 | $0.00 | $0.00 |
DisclosureSEC source: 0001438133-25-000037 · wk-form4_1740694513.xml · nonDerivative · entry 3 Sheridan John F · CIK 0001365369 · Director · PRESIDENT & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 89,017 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 25, 2025 Filed Feb 27, 2025 22:15 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | Tax withholdingCommon Stock | 3,419 | $33.34 | $113,989.46 |
DisclosureSEC source: 0001438133-25-000037 · wk-form4_1740694513.xml · nonDerivative · entry 2 Sheridan John F · CIK 0001365369 · Director · PRESIDENT & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 62,970 F1 · kind: Shares withheld by Tandem Diabetes Care, Inc. (the Company) to satisfy tax withholding requirements on vesting of performance stock units (PSU). No shares were sold. Read SEC document |
| February 25, 2025 Filed Feb 27, 2025 22:15 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | Exercise / conversionCommon Stock | 6,732 | $0.00 | $0.00 |
DisclosureSEC source: 0001438133-25-000037 · wk-form4_1740694513.xml · nonDerivative · entry 1 Sheridan John F · CIK 0001365369 · Director · PRESIDENT & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 66,389 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 18, 2025 Filed Feb 20, 2025 22:07 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | Exercise / conversionRestricted Stock Unit · Derivative | 5,472 | $0.00 | $0.00 |
DisclosureSEC source: 0001438133-25-000017 · wk-form4_1740089229.xml · derivative · entry 9 Sheridan John F · CIK 0001365369 · Director · PRESIDENT & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,358 Underlying: Common Stock · 5,472 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · security: Awarded on May 25, 2023 pursuant to the Tandem Diabetes Care, Inc. 2023 Long-Term Incentive Plan, as amended, and agreements related thereto (the 2023 Plan). F8 · derivative.exercise_price: Each RSU represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2023 Plan. F9 · derivative.exercise_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2024, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter. F9 · derivative.expiration_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2024, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter. Read SEC document |
| February 18, 2025 Filed Feb 20, 2025 22:07 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | Exercise / conversionRestricted Stock Unit · Derivative | 2,237 | $0.00 | $0.00 |
DisclosureSEC source: 0001438133-25-000017 · wk-form4_1740089229.xml · derivative · entry 8 Sheridan John F · CIK 0001365369 · Director · PRESIDENT & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,236 Underlying: Common Stock · 2,237 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · security: Awarded on May 25, 2022 pursuant to the 2013 Plan. F3 · derivative.exercise_price: Each RSU represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2013 Plan. F6 · derivative.exercise_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2023, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter. F6 · derivative.expiration_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2023, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter. Read SEC document |
| February 18, 2025 Filed Feb 20, 2025 22:07 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | Exercise / conversionRestricted Stock Unit · Derivative | 793 | $0.00 | $0.00 |
DisclosureSEC source: 0001438133-25-000017 · wk-form4_1740089229.xml · derivative · entry 7 Sheridan John F · CIK 0001365369 · Director · PRESIDENT & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 792 Underlying: Common Stock · 793 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Awarded on May 18, 2021 pursuant to the Tandem Diabetes Care, Inc. 2013 Stock Incentive Plan, as amended, and the agreements related thereto (the 2013 Plan). F3 · derivative.exercise_price: Each RSU represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2013 Plan. F4 · derivative.exercise_date: RSU vest as to twenty-five percent (25%) of the total number of shares subject to the RSU on 5/15/2022, and the remaining shares shall vest in twelve (12) equal quarterly installments thereafter. F4 · derivative.expiration_date: RSU vest as to twenty-five percent (25%) of the total number of shares subject to the RSU on 5/15/2022, and the remaining shares shall vest in twelve (12) equal quarterly installments thereafter. Read SEC document |
| February 18, 2025 Filed Feb 20, 2025 22:07 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | Tax withholdingCommon Stock | 2,097 | $33.47 | $70,186.59 |
DisclosureSEC source: 0001438133-25-000017 · wk-form4_1740089229.xml · nonDerivative · entry 6 Sheridan John F · CIK 0001365369 · Director · PRESIDENT & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 59,657 F1 · kind: Shares withheld by Tandem Diabetes Care, Inc. (the Company) to satisfy tax withholding requirements on vesting of restricted stock units (RSU). No shares were sold. Read SEC document |
| February 18, 2025 Filed Feb 20, 2025 22:07 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | Exercise / conversionCommon Stock | 5,472 | $0.00 | $0.00 |
DisclosureSEC source: 0001438133-25-000017 · wk-form4_1740089229.xml · nonDerivative · entry 5 Sheridan John F · CIK 0001365369 · Director · PRESIDENT & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 61,754 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 18, 2025 Filed Feb 20, 2025 22:07 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | Tax withholdingCommon Stock | 801 | $33.47 | $26,809.47 |
DisclosureSEC source: 0001438133-25-000017 · wk-form4_1740089229.xml · nonDerivative · entry 4 Sheridan John F · CIK 0001365369 · Director · PRESIDENT & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 56,282 F1 · kind: Shares withheld by Tandem Diabetes Care, Inc. (the Company) to satisfy tax withholding requirements on vesting of restricted stock units (RSU). No shares were sold. Read SEC document |
| February 18, 2025 Filed Feb 20, 2025 22:07 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | Exercise / conversionCommon Stock | 2,237 | $0.00 | $0.00 |
DisclosureSEC source: 0001438133-25-000017 · wk-form4_1740089229.xml · nonDerivative · entry 3 Sheridan John F · CIK 0001365369 · Director · PRESIDENT & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 57,083 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 18, 2025 Filed Feb 20, 2025 22:07 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | Tax withholdingCommon Stock | 284 | $33.47 | $9,505.48 |
DisclosureSEC source: 0001438133-25-000017 · wk-form4_1740089229.xml · nonDerivative · entry 2 Sheridan John F · CIK 0001365369 · Director · PRESIDENT & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 54,846 F1 · kind: Shares withheld by Tandem Diabetes Care, Inc. (the Company) to satisfy tax withholding requirements on vesting of restricted stock units (RSU). No shares were sold. Read SEC document |
| February 18, 2025 Filed Feb 20, 2025 22:07 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | Exercise / conversionCommon Stock | 793 | $0.00 | $0.00 |
DisclosureSEC source: 0001438133-25-000017 · wk-form4_1740089229.xml · nonDerivative · entry 1 Sheridan John F · CIK 0001365369 · Director · PRESIDENT & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,130 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 15, 2024 Filed Nov 19, 2024 22:22 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | Exercise / conversionRestricted Stock Unit · Derivative | 5,471 | $0.00 | $0.00 |
DisclosureSEC source: 0001438133-24-000210 · wk-form4_1732054936.xml · derivative · entry 10 Sheridan John F · CIK 0001365369 · Director · PRESIDENT & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,830 Underlying: Common Stock · 5,471 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · security: Awarded on May 25, 2023 pursuant to the Tandem Diabetes Care, Inc. 2023 Long-Term Incentive Plan, as amended, and agreements related thereto (the 2023 Plan). F9 · derivative.exercise_price: Each RSU represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2023 Plan. F10 · derivative.exercise_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2024, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter. F10 · derivative.expiration_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2024, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter. Read SEC document |
| November 15, 2024 Filed Nov 19, 2024 22:22 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | Exercise / conversionRestricted Stock Unit · Derivative | 2,236 | $0.00 | $0.00 |
DisclosureSEC source: 0001438133-24-000210 · wk-form4_1732054936.xml · derivative · entry 9 Sheridan John F · CIK 0001365369 · Director · PRESIDENT & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,473 Underlying: Common Stock · 2,236 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · security: Awarded on May 25, 2022 pursuant to the 2013 Plan. F4 · derivative.exercise_price: Each RSU represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2013 Plan. F7 · derivative.exercise_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2023, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter. F7 · derivative.expiration_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2023, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter. Read SEC document |
| November 15, 2024 Filed Nov 19, 2024 22:22 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | Exercise / conversionRestricted Stock Unit · Derivative | 792 | $0.00 | $0.00 |
DisclosureSEC source: 0001438133-24-000210 · wk-form4_1732054936.xml · derivative · entry 8 Sheridan John F · CIK 0001365369 · Director · PRESIDENT & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,585 Underlying: Common Stock · 792 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Awarded on May 18, 2021 pursuant to the Tandem Diabetes Care, Inc. 2013 Stock Incentive Plan, as amended, and the agreements related thereto (the 2013 Plan). F4 · derivative.exercise_price: Each RSU represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2013 Plan. F5 · derivative.exercise_date: RSU vest as to twenty-five percent (25%) of the total number of shares subject to the RSU on 5/15/2022, and the remaining shares shall vest in twelve (12) equal quarterly installments thereafter. F5 · derivative.expiration_date: RSU vest as to twenty-five percent (25%) of the total number of shares subject to the RSU on 5/15/2022, and the remaining shares shall vest in twelve (12) equal quarterly installments thereafter. Read SEC document |
| November 15, 2024 Filed Nov 19, 2024 22:22 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | GrantCommon Stock | 381 | $15.64 | $5,958.84 |
DisclosureSEC source: 0001438133-24-000210 · wk-form4_1732054936.xml · nonDerivative · entry 7 Sheridan John F · CIK 0001365369 · Director · PRESIDENT & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 54,337 F2 · shares: The reporting person is voluntarily reporting the acquisition of shares of common stock pursuant to the Tandem Diabetes Care, Inc. Amended and Restated 2013 Employee Stock Purchase Plan (ESPP), for the ESPP purchase period of May 16, 2024 through November 15, 2024. This transaction is also exempt under Rule 16b-3(c). Read SEC document |
| November 15, 2024 Filed Nov 19, 2024 22:22 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | Tax withholdingCommon Stock | 2,773 | $27.34 | $75,813.82 |
DisclosureSEC source: 0001438133-24-000210 · wk-form4_1732054936.xml · nonDerivative · entry 6 Sheridan John F · CIK 0001365369 · Director · PRESIDENT & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 53,956 F1 · kind: Shares withheld by Tandem Diabetes Care, Inc. (the Company) to satisfy tax withholding requirements on vesting of restricted stock units (RSU). No shares were sold. Read SEC document |
| November 15, 2024 Filed Nov 19, 2024 22:22 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | Exercise / conversionCommon Stock | 5,471 | $0.00 | $0.00 |
DisclosureSEC source: 0001438133-24-000210 · wk-form4_1732054936.xml · nonDerivative · entry 5 Sheridan John F · CIK 0001365369 · Director · PRESIDENT & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 56,729 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 15, 2024 Filed Nov 19, 2024 22:22 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | Tax withholdingCommon Stock | 1,134 | $27.34 | $31,003.56 |
DisclosureSEC source: 0001438133-24-000210 · wk-form4_1732054936.xml · nonDerivative · entry 4 Sheridan John F · CIK 0001365369 · Director · PRESIDENT & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,258 F1 · kind: Shares withheld by Tandem Diabetes Care, Inc. (the Company) to satisfy tax withholding requirements on vesting of restricted stock units (RSU). No shares were sold. Read SEC document |
| November 15, 2024 Filed Nov 19, 2024 22:22 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | Exercise / conversionCommon Stock | 2,236 | $0.00 | $0.00 |
DisclosureSEC source: 0001438133-24-000210 · wk-form4_1732054936.xml · nonDerivative · entry 3 Sheridan John F · CIK 0001365369 · Director · PRESIDENT & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,392 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 15, 2024 Filed Nov 19, 2024 22:22 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | Tax withholdingCommon Stock | 402 | $27.34 | $10,990.68 |
DisclosureSEC source: 0001438133-24-000210 · wk-form4_1732054936.xml · nonDerivative · entry 2 Sheridan John F · CIK 0001365369 · Director · PRESIDENT & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,156 F1 · kind: Shares withheld by Tandem Diabetes Care, Inc. (the Company) to satisfy tax withholding requirements on vesting of restricted stock units (RSU). No shares were sold. Read SEC document |
| November 15, 2024 Filed Nov 19, 2024 22:22 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | Exercise / conversionCommon Stock | 792 | $0.00 | $0.00 |
DisclosureSEC source: 0001438133-24-000210 · wk-form4_1732054936.xml · nonDerivative · entry 1 Sheridan John F · CIK 0001365369 · Director · PRESIDENT & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,558 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 15, 2024 Filed Aug 20, 2024 00:31 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | Exercise / conversionRestricted Stock Unit · Derivative | 5,472 | $0.00 | $0.00 |
DisclosureSEC source: 0001438133-24-000190 · wk-form4_1724113886.xml · derivative · entry 9 Sheridan John F · CIK 0001365369 · Director · PRESIDENT & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,301 Underlying: Common Stock · 5,472 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · security: Awarded on May 25, 2023 pursuant to the Tandem Diabetes Care, Inc. 2023 Long-Term Incentive Plan, as amended, and agreements related thereto (the 2023 Plan). F8 · derivative.exercise_price: Each RSU represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2023 Plan. F9 · derivative.exercise_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2024, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter. F9 · derivative.expiration_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2024, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter. Read SEC document |
| August 15, 2024 Filed Aug 20, 2024 00:31 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | Exercise / conversionRestricted Stock Unit · Derivative | 2,236 | $0.00 | $0.00 |
DisclosureSEC source: 0001438133-24-000190 · wk-form4_1724113886.xml · derivative · entry 8 Sheridan John F · CIK 0001365369 · Director · PRESIDENT & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,709 Underlying: Common Stock · 2,236 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · security: Awarded on May 25, 2022 pursuant to the 2013 Plan, as amended. F3 · derivative.exercise_price: Each RSU represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2013 Plan. F6 · derivative.exercise_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2023, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter, subject to the terms of the 2013 Plan. F6 · derivative.expiration_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2023, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter, subject to the terms of the 2013 Plan. Read SEC document |
| August 15, 2024 Filed Aug 20, 2024 00:31 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | Exercise / conversionRestricted Stock Unit · Derivative | 793 | $0.00 | $0.00 |
DisclosureSEC source: 0001438133-24-000190 · wk-form4_1724113886.xml · derivative · entry 7 Sheridan John F · CIK 0001365369 · Director · PRESIDENT & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,377 Underlying: Common Stock · 793 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Awarded on May 18, 2021 pursuant to the Tandem Diabetes Care, Inc. 2013 Stock Incentive Plan, as amended, and the agreements related thereto (the 2013 Plan). F3 · derivative.exercise_price: Each RSU represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2013 Plan. F4 · derivative.exercise_date: RSU vest as to twenty-five percent (25%) of the total number of shares subject to the RSU on 5/15/2022, and the remaining shares shall vest in twelve (12) equal quarterly installments thereafter, subject to the terms of the 2013 Plan. F4 · derivative.expiration_date: RSU vest as to twenty-five percent (25%) of the total number of shares subject to the RSU on 5/15/2022, and the remaining shares shall vest in twelve (12) equal quarterly installments thereafter, subject to the terms of the 2013 Plan. Read SEC document |
| August 15, 2024 Filed Aug 20, 2024 00:31 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | Tax withholdingCommon Stock | 2,774 | $43.82 | $121,556.68 |
DisclosureSEC source: 0001438133-24-000190 · wk-form4_1724113886.xml · nonDerivative · entry 6 Sheridan John F · CIK 0001365369 · Director · PRESIDENT & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,766 F1 · kind: Shares withheld by Tandem Diabetes Care, Inc. (the Company) to satisfy tax withholding requirements on vesting of restricted stock units (RSU). No shares were sold. Read SEC document |
| August 15, 2024 Filed Aug 20, 2024 00:31 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | Exercise / conversionCommon Stock | 5,472 | $0.00 | $0.00 |
DisclosureSEC source: 0001438133-24-000190 · wk-form4_1724113886.xml · nonDerivative · entry 5 Sheridan John F · CIK 0001365369 · Director · PRESIDENT & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,540 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 15, 2024 Filed Aug 20, 2024 00:31 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | Tax withholdingCommon Stock | 1,134 | $43.82 | $49,691.88 |
DisclosureSEC source: 0001438133-24-000190 · wk-form4_1724113886.xml · nonDerivative · entry 4 Sheridan John F · CIK 0001365369 · Director · PRESIDENT & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,068 F1 · kind: Shares withheld by Tandem Diabetes Care, Inc. (the Company) to satisfy tax withholding requirements on vesting of restricted stock units (RSU). No shares were sold. Read SEC document |
| August 15, 2024 Filed Aug 20, 2024 00:31 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | Exercise / conversionCommon Stock | 2,236 | $0.00 | $0.00 |
DisclosureSEC source: 0001438133-24-000190 · wk-form4_1724113886.xml · nonDerivative · entry 3 Sheridan John F · CIK 0001365369 · Director · PRESIDENT & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,202 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 15, 2024 Filed Aug 20, 2024 00:31 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | Tax withholdingCommon Stock | 402 | $43.82 | $17,615.64 |
DisclosureSEC source: 0001438133-24-000190 · wk-form4_1724113886.xml · nonDerivative · entry 2 Sheridan John F · CIK 0001365369 · Director · PRESIDENT & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,966 F1 · kind: Shares withheld by Tandem Diabetes Care, Inc. (the Company) to satisfy tax withholding requirements on vesting of restricted stock units (RSU). No shares were sold. Read SEC document |
| August 15, 2024 Filed Aug 20, 2024 00:31 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | Exercise / conversionCommon Stock | 793 | $0.00 | $0.00 |
DisclosureSEC source: 0001438133-24-000190 · wk-form4_1724113886.xml · nonDerivative · entry 1 Sheridan John F · CIK 0001365369 · Director · PRESIDENT & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,368 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 28, 2024 Filed May 28, 2024 22:44 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | Exercise / conversionRestricted Stock Unit · Derivative | 820 | $0.00 | $0.00 |
DisclosureSEC source: 0001438133-24-000141 · wk-form4_1716936272.xml · derivative · entry 5 Sheridan John F · CIK 0001365369 · Director · PRESIDENT & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 820 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · security: Awarded on May 27, 2020 pursuant to the Tandem Diabetes Care, Inc. 2013 Stock Incentive Plan, as amended, and the agreements related thereto (the 2013 Plan). F7 · derivative.exercise_price: Each RSU represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2013 Plan. F8 · derivative.exercise_date: RSU vest as to twenty-five percent (25%) of the total number of shares subject to the RSU on the one year anniversary of the grant date, and the remaining shares shall vest in twelve (12) equal quarterly installments thereafter, subject to the terms of the 2013 Plan. F8 · derivative.expiration_date: RSU vest as to twenty-five percent (25%) of the total number of shares subject to the RSU on the one year anniversary of the grant date, and the remaining shares shall vest in twelve (12) equal quarterly installments thereafter, subject to the terms of the 2013 Plan. Read SEC document |
| May 28, 2024 Filed May 28, 2024 22:44 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | Tax withholdingCommon Stock | 416 | $51.73 | $21,519.68 |
DisclosureSEC source: 0001438133-24-000141 · wk-form4_1716936272.xml · nonDerivative · entry 2 Sheridan John F · CIK 0001365369 · Director · PRESIDENT & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,575 F1 · kind: Shares withheld by Tandem Diabetes Care, Inc. (the Company) to satisfy tax withholding requirements on vesting of restricted stock units (RSU). No shares were sold. Read SEC document |
| May 28, 2024 Filed May 28, 2024 22:44 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | Exercise / conversionCommon Stock | 820 | $0.00 | $0.00 |
DisclosureSEC source: 0001438133-24-000141 · wk-form4_1716936272.xml · nonDerivative · entry 1 Sheridan John F · CIK 0001365369 · Director · PRESIDENT & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,991 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 23, 2024 Filed May 28, 2024 22:44 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | GrantPerformance Stock Unit · Derivative | 71,787 | $0.00 | $0.00 |
DisclosureSEC source: 0001438133-24-000141 · wk-form4_1716936272.xml · derivative · entry 4 Sheridan John F · CIK 0001365369 · Director · PRESIDENT & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 71,787 Underlying: Common Stock · 71,787 shares Expires not disclosed F2 · security: Awarded on May 23, 2024 pursuant to the Tandem Diabetes Care, Inc. 2023 Long-Term Incentive Plan (the 2023 Plan). F5 · derivative.exercise_price: Each performance stock unit (PSU) represents a contingent right to receive one share of Tandem Diabetes Care, Inc. (the Company) common stock based upon the achievement of certain pre-defined performance metrics as of December 31, 2026 (the Measurement Date). The number of shares issued may range from 0% to 200% of the amount specified above, based upon (i) Company's actual performance relative to the pre-defined performance metrics, and (ii) subject to the awardee's continuing service through the Measurement Date. If minimum performance metrics are not met, no PSUs will vest. F5 · derivative.exercise_date: Each performance stock unit (PSU) represents a contingent right to receive one share of Tandem Diabetes Care, Inc. (the Company) common stock based upon the achievement of certain pre-defined performance metrics as of December 31, 2026 (the Measurement Date). The number of shares issued may range from 0% to 200% of the amount specified above, based upon (i) Company's actual performance relative to the pre-defined performance metrics, and (ii) subject to the awardee's continuing service through the Measurement Date. If minimum performance metrics are not met, no PSUs will vest. F5 · derivative.expiration_date: Each performance stock unit (PSU) represents a contingent right to receive one share of Tandem Diabetes Care, Inc. (the Company) common stock based upon the achievement of certain pre-defined performance metrics as of December 31, 2026 (the Measurement Date). The number of shares issued may range from 0% to 200% of the amount specified above, based upon (i) Company's actual performance relative to the pre-defined performance metrics, and (ii) subject to the awardee's continuing service through the Measurement Date. If minimum performance metrics are not met, no PSUs will vest. Read SEC document |
| May 23, 2024 Filed May 28, 2024 22:44 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | GrantRestricted Stock Unit · Derivative | 71,787 | $0.00 | $0.00 |
DisclosureSEC source: 0001438133-24-000141 · wk-form4_1716936272.xml · derivative · entry 3 Sheridan John F · CIK 0001365369 · Director · PRESIDENT & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 71,787 Underlying: Common Stock · 71,787 shares Expires not disclosed F2 · security: Awarded on May 23, 2024 pursuant to the Tandem Diabetes Care, Inc. 2023 Long-Term Incentive Plan (the 2023 Plan). F3 · derivative.exercise_price: Each restricted stock unit (RSU) represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2023 Plan. F4 · derivative.exercise_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2025, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter. F4 · derivative.expiration_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2025, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter. Read SEC document |
| May 15, 2024 Filed May 17, 2024 21:45 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | Exercise / conversionRestricted Stock Unit · Derivative | 21,886 | $0.00 | $0.00 |
DisclosureSEC source: 0001438133-24-000096 · wk-form4_1715982328.xml · derivative · entry 10 Sheridan John F · CIK 0001365369 · Director · PRESIDENT & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,773 Underlying: Common Stock · 21,886 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · security: Awarded on May 25, 2023 pursuant to the Tandem Diabetes Care, Inc. 2023 Long-Term Incentive Plan (the 2023 Plan). F9 · derivative.exercise_price: Each RSU represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2023 Plan. F10 · derivative.exercise_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2024, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter. F10 · derivative.expiration_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2024, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter. Read SEC document |
| May 15, 2024 Filed May 17, 2024 21:45 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | Exercise / conversionRestricted Stock Unit · Derivative | 2,237 | $0.00 | $0.00 |
DisclosureSEC source: 0001438133-24-000096 · wk-form4_1715982328.xml · derivative · entry 9 Sheridan John F · CIK 0001365369 · Director · PRESIDENT & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,945 Underlying: Common Stock · 2,237 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · security: Awarded on May 25, 2022 pursuant to the 2013 Plan. F4 · derivative.exercise_price: Each RSU represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2013 Plan. F7 · derivative.exercise_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2023, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter. F7 · derivative.expiration_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2023, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter. Read SEC document |
| May 15, 2024 Filed May 17, 2024 21:45 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | Exercise / conversionRestricted Stock Unit · Derivative | 792 | $0.00 | $0.00 |
DisclosureSEC source: 0001438133-24-000096 · wk-form4_1715982328.xml · derivative · entry 8 Sheridan John F · CIK 0001365369 · Director · PRESIDENT & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,170 Underlying: Common Stock · 792 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Awarded on May 18, 2021 pursuant to the Tandem Diabetes Care, Inc. 2013 Stock Incentive Plan, as amended, and the agreements related thereto (the 2013 Plan). F4 · derivative.exercise_price: Each RSU represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2013 Plan. F5 · derivative.exercise_date: RSU vest as to twenty-five percent (25%) of the total number of shares subject to the RSU on 5/15/2022, and the remaining shares shall vest in twelve (12) equal quarterly installments thereafter. F5 · derivative.expiration_date: RSU vest as to twenty-five percent (25%) of the total number of shares subject to the RSU on 5/15/2022, and the remaining shares shall vest in twelve (12) equal quarterly installments thereafter. Read SEC document |
| May 15, 2024 Filed May 17, 2024 21:45 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | Tax withholdingCommon Stock | 9,074 | $47.37 | $429,835.38 |
DisclosureSEC source: 0001438133-24-000096 · wk-form4_1715982328.xml · nonDerivative · entry 7 Sheridan John F · CIK 0001365369 · Director · PRESIDENT & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,171 F2 · kind: Shares withheld by Tandem Diabetes Care, Inc. (the Company) to satisfy tax withholding requirements on vesting of restricted stock units (RSU). No shares were sold. Read SEC document |
| May 15, 2024 Filed May 17, 2024 21:45 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | Exercise / conversionCommon Stock | 21,886 | $0.00 | $0.00 |
DisclosureSEC source: 0001438133-24-000096 · wk-form4_1715982328.xml · nonDerivative · entry 6 Sheridan John F · CIK 0001365369 · Director · PRESIDENT & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 54,245 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 15, 2024 Filed May 17, 2024 21:45 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | Tax withholdingCommon Stock | 1,134 | $47.37 | $53,717.58 |
DisclosureSEC source: 0001438133-24-000096 · wk-form4_1715982328.xml · nonDerivative · entry 5 Sheridan John F · CIK 0001365369 · Director · PRESIDENT & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,359 F2 · kind: Shares withheld by Tandem Diabetes Care, Inc. (the Company) to satisfy tax withholding requirements on vesting of restricted stock units (RSU). No shares were sold. Read SEC document |
| May 15, 2024 Filed May 17, 2024 21:45 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | Exercise / conversionCommon Stock | 2,237 | $0.00 | $0.00 |
DisclosureSEC source: 0001438133-24-000096 · wk-form4_1715982328.xml · nonDerivative · entry 4 Sheridan John F · CIK 0001365369 · Director · PRESIDENT & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,493 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 15, 2024 Filed May 17, 2024 21:45 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | Tax withholdingCommon Stock | 402 | $47.37 | $19,042.74 |
DisclosureSEC source: 0001438133-24-000096 · wk-form4_1715982328.xml · nonDerivative · entry 3 Sheridan John F · CIK 0001365369 · Director · PRESIDENT & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,256 F2 · kind: Shares withheld by Tandem Diabetes Care, Inc. (the Company) to satisfy tax withholding requirements on vesting of restricted stock units (RSU). No shares were sold. Read SEC document |
| May 15, 2024 Filed May 17, 2024 21:45 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | Exercise / conversionCommon Stock | 792 | $0.00 | $0.00 |
DisclosureSEC source: 0001438133-24-000096 · wk-form4_1715982328.xml · nonDerivative · entry 2 Sheridan John F · CIK 0001365369 · Director · PRESIDENT & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,658 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 15, 2024 Filed May 17, 2024 21:45 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | GrantCommon Stock | 978 | $15.64 | $15,295.92 |
DisclosureSEC source: 0001438133-24-000096 · wk-form4_1715982328.xml · nonDerivative · entry 1 Sheridan John F · CIK 0001365369 · Director · PRESIDENT & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,866 F1 · shares: The reporting person is voluntarily reporting the acquisition of shares of common stock pursuant to the Tandem Diabetes Care, Inc. Amended and Restated 2013 Employee Stock Purchase Plan (ESPP), for the ESPP purchase period of November 16, 2023 through May 15, 2024. This transaction is also exempt under Rule 16b-3(c). Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.